(Q42675082)

4 November 2017

title

Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating δ9-tetrahydrocannabinol (English)

1 reference

4 November 2017

Substitution Profile of the Cannabinoid Agonist Nabilone in Human Subjects Discriminating Δ9-Tetrahydrocannabinol (English)

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

human subject research project

12 July 2024

main subject

0 references

0 references

0 references

Joshua A. Lile

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20838217

12 July 2024

Thomas H. Kelly

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20838217

12 July 2024

Lon R. Hays

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20838217

12 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20838217

12 July 2024

publication date

1 September 2010

1 reference

full work available at URL

4 November 2017

https://journals.lww.com/10.1097/WNF.0b013e3181e77428

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Clinical Neuropharmacology

12 July 2024

published in

1 reference

4 November 2017

volume

33

1 reference

4 November 2017

issue

5

1 reference

4 November 2017

page(s)

235-242

1 reference

Reinforcing and subjective effects of oral Δ9-THC and smoked marijuana in humans

4 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans

12 July 2024

2

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids.

12 July 2024

3

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans.

12 July 2024

4

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

The functional neuroanatomy of brain cannabinoid receptors

12 July 2024

6

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

(-)-Adamantyl-delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats

12 July 2024

7

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356).

12 July 2024

8

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats

12 July 2024

9

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol

12 July 2024

10

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy

12 July 2024

11

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833

12 July 2024

12

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats

12 July 2024

14

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys

12 July 2024

16

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625.

12 July 2024

17

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users

12 July 2024

18

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.

12 July 2024

19

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety

12 July 2024

20

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies

12 July 2024

21

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers

12 July 2024

22

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Discriminative Stimulus Properties of Δ9-Tetrahydrocannabinol: Mechanistic Studies

12 July 2024

26

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

A single dose study of nabilone, a synthetic cannabinoid

12 July 2024

27

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Single-Dose Study of Nabilone in Anxious Volunteers

12 July 2024

28

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Nabilone. A preliminary review of its pharmacological properties and therapeutic use.

12 July 2024

29

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Safety issues concerning the medical use of cannabis and cannabinoids

12 July 2024

30

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Pharmacokinetics, metabolism and drug-abuse potential of nabilone

12 July 2024

31

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Reinforcing properties of oral delta 9-tetrahydrocannabinol, smoked marijuana, and nabilone: influence of previous marijuana use.

12 July 2024

32

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol

12 July 2024

34

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

The reinforcing, self-reported performance and physiological effects of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in cannabis users

12 July 2024

37

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence

12 July 2024

39

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain

12 July 2024

40

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Flunitrazepam and triazolam: a comparison of behavioral effects and abuse liability.

12 July 2024

41

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Zaleplon and triazolam in humans: acute behavioral effects and abuse potential

12 July 2024

42

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy

12 July 2024

43

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Abuse liability assessment of sibutramine, a novel weight control agent

12 July 2024

44

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Pharmacological determinants of the reinforcing effects of psychostimulants: relation to agonist substitution treatment

12 July 2024

45

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts

12 July 2024

46

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Effects of oral THC maintenance on smoked marijuana self-administration

12 July 2024

47

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Effects of delta 9-THC on marijuana smoking, dose choice, and verbal report of drug liking

12 July 2024

48

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study

12 July 2024

49

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

The effect of nabilone on neuropsychological functions related to driving ability: an extended case series

12 July 2024

50

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure

12 July 2024

51

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

The effects of delta(9)-tetrahydrocannabinol on repeated acquisition and performance of response sequences and on self-reports in humans.

12 July 2024

52

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Cannabis and alcohol: Effects on estimation of time and distance

12 July 2024

53

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports, and performance.

12 July 2024

54

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Multidimensional behavioral effects of marijuana

12 July 2024

55

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol, and diazepam.

12 July 2024

56

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Antagonism of marihuana effects by indomethacin in humans

12 July 2024

57

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Effects of marijuana on performance of a computerized cognitive-neuromotor test battery.

12 July 2024

58

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers

12 July 2024

59

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Effects of acute smoked marijuana on complex cognitive performance

12 July 2024

60

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Effects of THC on behavioral measures of impulsivity in humans

12 July 2024

61

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Effects of abused drugs on psychomotor performance.

12 July 2024

62

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Assessing cognitive functioning in cannabis users: cannabis use history an important consideration

12 July 2024

63

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Nicotine replacement therapy

12 July 2024

64

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.

12 July 2024

65

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine

12 July 2024

66

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms

12 July 2024

67

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Marijuana Withdrawal in Humans: Effects of Oral THC or Divalproex

12 July 2024

68

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

Clinical relevance of cannabis tolerance and dependence

12 July 2024

69

1 reference

https://api.crossref.org/works/10.1097/WNF.0B013E3181E77428

12 July 2024

Identifiers

1 reference

4 November 2017

1 reference